Apellis Pharmaceuticals, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Director A. Sinclair Dunlop reports the disposal of all equity holdings in Apellis Pharmaceuticals following its acquisition by Biogen.
NASDAQ
Apellis Pharmaceuticals has been acquired by Biogen in a transaction valued at $41.00 per share plus a contingent value right.
NASDAQ
Director Mikael Dolsten reports the disposition of all Apellis Pharmaceuticals equity holdings following the company's acquisition by Biogen.
NASDAQ
Apellis Pharmaceuticals has been acquired by Biogen in a transaction valued at $41.00 per share plus a contingent value right.
NASDAQ
Director Paul Fonteyne reports the disposition of all Apellis Pharmaceuticals equity holdings following the company's acquisition by Biogen.
NASDAQ
Apellis Pharmaceuticals has been acquired by Biogen in a transaction effective May 14, 2026, resulting in the delisting of its common stock.
NASDAQ
Apellis Pharmaceuticals has been acquired by Biogen in a merger transaction effective May 14, 2026.
NASDAQ
Apellis Pharmaceuticals has been acquired by Biogen in a transaction involving $41.00 per share in cash plus a contingent value right.
NASDAQ
Director Gerald Chan reports the disposition of all equity holdings in Apellis Pharmaceuticals following its acquisition by Biogen.
NASDAQ
Apellis Pharmaceuticals has been acquired by Biogen in a transaction valued at $41.00 per share plus a contingent value right.
NASDAQ
Director Keli Walbert reports the disposal of all equity holdings in Apellis Pharmaceuticals following the company's acquisition by Biogen.
NASDAQ
Apellis Pharmaceuticals has been acquired by Biogen in a transaction where shares were converted into $41.00 cash plus a contingent value right.
NASDAQ
Apellis Pharmaceuticals has been acquired by Biogen in a transaction valued at $41.00 per share plus contingent value rights.
NASDAQ
Apellis Pharmaceuticals has been acquired by Biogen in a transaction valued at $41.00 per share plus a contingent value right.
NASDAQ
Director Craig A. Wheeler reports the disposition of all equity holdings in Apellis Pharmaceuticals following its acquisition by Biogen.
NASDAQ
Apellis Pharmaceuticals has been acquired by Biogen in a transaction valued at $41.00 per share plus a contingent value right.
NASDAQ
Apellis Pharmaceuticals has been acquired by Biogen in a transaction valued at $41.00 per share plus a contingent value right.
NASDAQ
Apellis Pharmaceuticals has been acquired by Biogen in a transaction involving a $41.00 per share cash payment plus contingent value rights.
NASDAQ
Chief Medical Officer Caroline Baumal donated 900 shares of Apellis Pharmaceuticals to charity while maintaining a substantial ownership stake.
NASDAQ
Apellis Pharmaceuticals CFO Timothy Sullivan transferred 11,096 shares to an irrevocable trust for estate planning purposes.
NASDAQ
Stephanie O'Brien, a Director at Apellis Pharmaceuticals, reported a transaction involving 5,750 shares of common stock.
NASDAQ
Apellis Pharmaceuticals CEO Cedric Francois reported a transfer of 64,869 shares of common stock to an irrevocable trust for estate planning.
NASDAQ
Apellis Pharmaceuticals director Mikael Dolsten was granted 14,312 restricted stock units and 24,135 stock options on February 27, 2026, aligning his interests with shareholders.
NASDAQ
Apellis Pharmaceuticals' Chief Business & Strategy Officer, Mark DeLong, sold 368 shares of common stock to cover tax obligations related to restricted stock unit vesting.
NASDAQ
Apellis Pharmaceuticals CEO Cedric Francois exercised 8,840 stock options at $3.76 per share, increasing his direct beneficial ownership.
NASDAQ
Apellis Pharmaceuticals' Chief People Officer, Kelley Boucher, received a grant of 30,146 Restricted Stock Units, vesting over four years.
NASDAQ
Apellis Pharmaceuticals' VP/Chief Accounting Officer, James Chopas, was granted 16,150 Restricted Stock Units vesting over four years.
NASDAQ
Apellis Pharmaceuticals' Chief Business & Strategy Officer, Mark DeLong, was granted 36,606 Restricted Stock Units.
NASDAQ
Apellis Pharmaceuticals' Chief Scientific Officer, Pascal Deschatelets, received an award of 25,840 Restricted Stock Units vesting over four years.
NASDAQ
Apellis Pharmaceuticals' Chief Research and Development Officer, Leslie Meltzer, was granted 45,220 Restricted Stock Units.